Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma

NCT01505608 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT01505608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01505608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2011
Completion date
December 31, 2014
Enrollment
14 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma